ADEP-14
Based on 1 Customer Validation
ADEP-14 (ADEP26) is a ClpP activator. ADEP-14 exhibits antibacterial activity against Gram-negative and Gram-positive bacteria. ADEP-14 can be used in studies related to bacterial infections.
For research use only. We do not sell to patients.
- Purity : 98.33%
- CAS No.: 1846579-07-4
- Formula: C41H54F2N6O8
- Molecular Weight:796.90
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Description
In Vitro
ADEP-14 (preincubated for 10 min) potently activates the proteolytic activity of purified Neisseria meningitidis ClpP and Escherichia coli ClpP in casein-FITC degradation assays. It exhibits high binding affinity, and its EC50 value shows a linear correlation with ClpP concentration[1].
ADEP-14 (Compound 26) potently inhibits the growth of wild-type Neisseria meningitidis H44/76 (MIC = 0.0313 μg/mL) and Neisseria gonorrhoeae N.279 (MIC = 0.0078 μg/mL). Its activity depends on functional ClpP, and it exhibits only limited activity against membrane-compromised Escherichia coli strains (MIC = 4 μg/mL)[2].
ADEP-14 potently inhibits the growth of all tested Gram-positive strains, including MRSA (MIC = 0.125 μg/mL) and VRE (MIC = 0.0039 μg/mL); for Streptococcus pneumoniae D39, Bacillus subtilis PY79 and Listeria innocua, its MIC values are ≤0.0625 μg/mL[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1846579-07-4
-
Appearance Solid
-
Molecular Weight 796.90
-
Formula C41H54F2N6O8
-
SMILES
[H][C@@]12C[C@H](CN1C([C@@H](NC([C@@]3(CCCCN3C([C@@]4(CCCN4C([C@H]([C@@H](OC2=O)C)NC([C@@H](NC(/C=C/C=C/CCC)=O)CC5=CC(F)=CC(F)=C5)=O)=O)[H])=O)[H])=O)C)=O)C
-
Synonyms
ADEP26
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro:
DMSO : 10 mg/mL (12.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Purity & Documentation
References
[1]. Barghash MM, et al. Small molecule dysregulation of ClpP activity via bidirectional allosteric pathways. Structure. 2025;33(10):1700-1716.e6. [Content Brief]
[2]. Goodreid JD, et al. Development and Characterization of Potent Cyclic Acyldepsipeptide Analogues with Increased Antimicrobial Activity. J Med Chem. 2016;59(2):624-646. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2549 mL | 6.2743 mL | 12.5486 mL | 31.3716 mL |
| 5 mM | 0.2510 mL | 1.2549 mL | 2.5097 mL | 6.2743 mL | |
| 10 mM | 0.1255 mL | 0.6274 mL | 1.2549 mL | 3.1372 mL |